Article Information
History
- September 22, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Danuta M Skowronski1,2,*,
- Solmaz Setayeshgar1,#,
- Macy Zou3,
- Natalie Prystajecky4,5,
- John R Tyson4,5,
- Hind Sbihi2,3,
- Chris D Fjell4,
- Eleni Galanis1,2,
- Monika Naus1,2,
- David M Patrick1,2,
- Shiraz El Adam1,
- May Ahmed1,
- Shinhye Kim1,
- Bonnie Henry2,6,
- Linda M N Hoang4,5,
- Manish Sadarangani7,8,
- Agatha N Jassem4,5 and
- Mel Krajden4,5
- 1BC Centre for Disease Control, Communicable Diseases and Immunization Services, Vancouver, British Columbia, Canada
- 2University of British Columbia, School of Population and Public Health, Vancouver, British Columbia, Canada
- 3BC Centre for Disease Control, Data and Analytics Services, Vancouver, British Columbia, Canada
- 4BC Centre for Disease Control, Public Health Laboratory, Vancouver, British Columbia, Canada
- 5University of British, Department of Pathology and Laboratory Medicine, Vancouver, British Columbia, Canada
- 6Office of the Provincial Health Officer, Ministry of Health, Victoria, British Columbia, Canada
- 7Vaccine Evaluation Center, BC Children’s Hospital Research Institute, Vancouver, British Columbia, Canada
- 8University of British Columbia, Department of Pediatrics, Vancouver, British Columbia, Canada
- ↵*Corresponding Author:
Danuta M Skowronski MD, FRCPC, 655 West 12th Avenue, Vancouver, British Columbia, Canada V5Z 4R4, Ph: 604-707-2511, E-mail: danuta.skowronski{at}bccdc.ca - ↵#Alternate corresponding author:
Solmaz Setayeshgar PhD, 655 West 12th Avenue, Vancouver, British Columbia, Canada V5Z 4R4, Ph: 604-707-2517, E-mail: solmaz.setayeshgar{at}bccdc.ca
Posted September 22, 2021.
Comparative single-dose mRNA and ChAdOx1 vaccine effectiveness against SARS-CoV-2, including early variants of concern: a test-negative design, British Columbia, Canada
